Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Prolocor logo — Advancing patient care by empowering physicians with effecti...

Prolocor

Advancing patient care by empowering physicians with effective precision diagnostics for cardiovascular disease.

Founded 2020 United States Philadelphia, United States 8 employees Convertible Note Total: $6.90M Biotechnology, Health Care

General Information

Company Name Prolocor
Founded Year 2020
Location United States Philadelphia, United States
Founders / Decision Makers
Team member
Employees 8
Industries Biotechnology, Health Care
Funding Stage Convertible Note
Social

BounceWatch is an independent company data service, not affiliated with Prolocor. To contact Prolocor, visit prolocor.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Prolocor compare?

A PDF of Prolocor and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Prolocor soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Prolocor

Prolocor is a biotechnology startup that aims to revolutionize patient care in cardiovascular disease. With a focus on precision diagnostics, Prolocor addresses the critical treatment decision-making process for the 50 million individuals living with chronic coronary artery disease in the U.S., Europe, and Japan. The company's innovative precision tool, led by a team deeply versed in thrombosis and cardiovascular disease, aims to guide treatment decisions by matching therapy intensity with the risk of events. Prolocor's groundbreaking strategy centers around platelet FcγRIIa and introduces a pioneering precision diagnostic test that quantifies FcγRIIa on the surface of platelets. Founded in 2020, the company secured a notable $1.70MConvertible Note investment on 27 February 2024 with the backing of Green Park & Golf Ventures and the LabCorp Venture Fund. Operating from the United States, Prolocor stands at the forefront of advancing the field of cardiovascular care with its innovative approach, poised for significant impact in the biotechnology and healthcare sectors.

Business keywords: precision diagnostics, cardiovascular disease, chronic coronary artery disease, acute coronary syndrome, therapy decision-making, thrombosis, platelet FcγRIIa, commercialization strategy, precision diagnostic test, cardiovascular risk assessment, bleeding risk assessment, heart attack prevention, stroke prevention, cardiovascular death prevention

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note $1.70M 2
Green Park & Golf Ventures
Green Park & Golf Ventures, LabCorp Venture Fund
27 Feb 2024
Seed Round $3.20M 2
Green Park & Golf Ventures LabCorp
Green Park & Golf Ventures, LabCorp
16 Aug 2022
Grant $2.00M 1
Small Business Innovation Research
16 Aug 2022

Prolocor Alternatives & Competitors

View All Alternatives
Prolocor vs
GENinCode Predictive Genetics
GENinCode Predictive Genetics United Kingdom

Clinical Genetics and Precision Medicine. Safeguarding your future health.

Post-IPO Equity
47 employees
Biotechnology, Health Care
Compare Prolocor vs GENinCode Predictive Genetics
Prolocor vs
Iverson Genetic Diagnostics
Iverson Genetic Diagnostics

Your partner in diagnosing and treating chronic diseases, offering advanced genetic tests for precis...

Debt Financing
Biotechnology, Health Care
Prolocor vs
CardioDx
CardioDx

Empowering personalized cardiovascular care through advanced genomic diagnostics.

Venture round
Biotechnology, Health Care
View all alternatives

FAQ About Prolocor

Advancing patient care by empowering physicians with effective precision diagnostics for cardiovascular disease.
Prolocor was founded in 2020.
Prolocor is headquartered in Philadelphia, United States.
Prolocor operates in Biotechnology and Health Care. Its work centres on precision diagnostics, cardiovascular disease, chronic coronary artery disease and acute coronary syndrome.
Prolocor has approximately 8 employees.
Prolocor has completed 3 funding rounds, raising a total of $6.90M. The latest funding stage is Convertible Note.
Top alternatives and competitors to Prolocor include GENinCode Predictive Genetics , Iverson Genetic Diagnostics, CardioDx, Artrya Ltd, Cleveland HeartLab, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Prolocor and GENinCode Predictive Genetics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Prolocor, https://bouncewatch.com/company/prolocor, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout